Simultaneous targeting of IL-10 and PD-(L)1 pathways with a bispecific anti-PD-L1/IL-10-trap antibody enhances T cell responses

This is the authors' abstract. We don't add key points for this paper.

T cell activation compared with anti-PD-(L)1, IL-10-trap, or their combination. Our data support the immunosuppressive role of IL-10 in tumors and demonstrate that simultaneous targeting of PD-L1 and IL-10 may provide superior T cell responses compared to anti-PD-(L)1 therapies alone or in combination with anti-IL-10 antibodies.